Usefulness of F-18 FDG-PET in a long-term hemodialysis patient with renal cell carcinoma and pheochromocytoma

[1]  J. Carrasquillo,et al.  Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites , 2006, Nuclear medicine communications.

[2]  S. Ezuddin,et al.  MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. , 2005, Clinical nuclear medicine.

[3]  H. Sasser,et al.  Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. , 2004, The Journal of urology.

[4]  J. Bargman,et al.  Renal cell carcinoma in peritoneal dialysis patients , 2003, International Urology and Nephrology.

[5]  Y. Shiau,et al.  Differentiating Solitary Pulmonary Metastases in Patients with Renal Cell Carcinomas by 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography – A Preliminary Report , 2003, Urologia Internationalis.

[6]  Tatsuya Kobayashi,et al.  Incidentally discovered pheochromocytoma in long‐term hemodialysis patients , 2002, International journal of urology : official journal of the Japanese Urological Association.

[7]  C. Kao,et al.  Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas – a preliminary report , 2002, Journal of Cancer Research and Clinical Oncology.

[8]  Marc Seltzer,et al.  Positron emission tomography in urologic oncology. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[9]  C. Ohyama,et al.  Adrenal metastasis from renal cell carcinoma: Significance of adrenalectomy , 2002, International journal of urology : official journal of the Japanese Urological Association.

[10]  S. Yasuda,et al.  Significance of 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT‐1) expression in the cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.

[11]  S. Berlangieri,et al.  Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. , 2001, The Journal of urology.

[12]  John A. Godfrey,et al.  Pheochromocytoma in a patient with end-stage renal disease. , 2001, Mayo Clinic proceedings.

[13]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[14]  R. Motzer,et al.  Renal-cell carcinoma. , 1996, The New England journal of medicine.

[15]  E. Bravo,et al.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.

[16]  D. O'Connor,et al.  Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure. , 1990, Kidney international.

[17]  N. Vaziri,et al.  Plasma Norepinephrine, Epinephrine, and Dopamine Levels in End-Stage Renal Disease: Effect of Hemodialysis , 1985 .

[18]  M. Rossleigh,et al.  Superiority of F-18 FDG PET imaging for detection of a pheochromocytoma. , 2006, Clinical nuclear medicine.

[19]  T. Bley,et al.  Imaging of pheochromocytoma and paraganglioma , 2004, Familial Cancer.

[20]  M. Stumvoll,et al.  Diagnostic considerations in pheochromocytoma and chronic hemodialysis: case report and review of the literature. , 1995, American journal of nephrology.